NVP-BAW2881 | BAW2881 | VEGFR Inhibitor | AmBeed-信号通路专用抑制剂

首页 / / / VEGFR / NVP-BAW2881

NVP-BAW2881 {[allProObj[0].p_purity_real_show]}

货号：A142514 同义名： BAW2881

NVP-BAW2881是一种血管内皮生长因子（VEGF）抑制剂，IC50值在1.0 nM至4.3 nM之间，针对VEGFR1、VEGFR2、VEGFR3。它还能够抑制PDGFRβ、c-Kit和RET的活性。

NVP-BAW2881 化学结构
CAS号：861875-60-7

NVP-BAW2881 3D分子结构
CAS号：861875-60-7

规格	价格	会员价	库存	数量
{[ item.pr_size ]}	{[ getRatePriceInt(item.pr_rmb, 1,1) ]} {[ getRatePriceInt(item.pr_rmb_sale, 1,1) ]} {[ suihuo_tips(item.pr_tag_price, item.pr_am) ]}	{[ getRatePriceInt(item.pr_rmb, 1,1) ]} {[ getRatePriceInt(item.pr_rmb,item.pr_rate,1) ]} {[ suihuo_tips(item.pr_tag_price, item.pr_am) ]}	{[ getRatePriceInt(item.pr_rmb, 1,1) ]}{[ suihuo_tips(item.pr_tag_price, item.pr_am) ]}	{[ getRatePrice(item.pr_rmb_sale, 1,1,item.mem_isinteger) ]} {[ getRatePrice(item.pr_rmb,item.pr_rate,item.mem_rate,item.mem_isinteger) ]} {[ getRatePrice(item.pr_rmb,1,item.mem_rate,item.mem_isinteger) ]}	现货	1周咨询	- +

购物车0 收藏询单

sales@ambeed.cn tech@ambeed.cn 400-920-2911 产品手册产品订购技术咨询
快速发货顺丰冷链运输，1-2 天到达

品质保证

技术支持

免费溶解

NVP-BAW2881 纯度/质量文件产品仅供科研

货号：A142514 标准纯度： {[allProObj[0].p_purity_real_show]} 产品说明书

批次查询：批次纯度: COA SDS NMR HPLC CNMR LC-MS

全球学术期刊中引用的产品: • Nature, 2025, 645, 793-800. Ambeed. [ A201204 , A444152 , A344107 , A952055 ]; • Cell, 2025. Ambeed. [ A122167 ]; • Science, 2025, 387(6729): eadp5637. Ambeed. [ A875019 ]; • Sig. Transduct. Target. Ther., 2025, 10, 257. Ambeed. [ A104916 ]; • Nat. Nanotechnol., 2025. Ambeed. [ A243018 , A1216705 , A522597 , A125401 , A1355641 ]; 更多 >

VEGFR 亚型比较

产品名称	VEGFR1 ↓ ↑	VEGFR2 ↓ ↑	VEGFR3 ↓ ↑	其他靶点	纯度
Motesanib Diphosphate	++++ VEGFR1, IC50: 2 nM	++++ VEGFR2/Flk1, IC50: 3 nM VEGFR2, IC50: 3 nM	+++ VEGFR3, IC50: 6 nM	RET,PDGFR	97%
Tivozanib	++ VEGFR1, IC50: 30 nM	+++ VEGFR2, IC50: 6.5 nM	++ VEGFR3, IC50: 15 nM		99%+
Brivanib	+ VEGFR1, IC50: 380 nM	++ Flk1, IC50: 25 nM VEGFR2, IC50: 25 nM			99%+
Regorafenib	+++ VEGFR1, IC50: 13 nM	+++ VEGFR2, IC50: 4.2 nM	+ VEGFR3, IC50: 46 nM	RET	98%
Pazopanib	+++ VEGFR1, IC50: 10 nM	++ VEGFR2, IC50: 30 nM	+ VEGFR3, IC50: 47 nM	c-Kit,PDGFR,FGFR	99%
Sitravatinib	+++ VEGFR1 (FLT1), IC50: 6 nM	+++ VEGFR2 (KDR), IC50: 5 nM	++++ VEGFR3 (FLT4), IC50: 2 nM		99%+
Foretinib	+++ VEGFR1/FLT1, IC50: 6.8 nM	++++ KDR, IC50: 0.86 nM	++++ VEGFR3/FLT4, IC50: 2.8 nM	Tie-2	99%+
MGCD-265 analog	++++ VEGFR1, IC50: 3 nM	++++ VEGFR2, IC50: 3 nM	++++ VEGFR3, IC50: 4 nM	Tie-2	99%+
Lactate	+++ VEGFR1/FLT1, IC50: 10 nM	+++ VEGFR2/Flk1, IC50: 13 nM	+++ VEGFR3/FLT4, IC50: 8 nM	FLT3,c-Kit	85%
AEE788	+ FLT1, IC50: 59 nM	+ KDR, IC50: 77 nM		EGFR	98+%
Linifanib	++++ VEGFR1/FLT1, IC50: 3 nM	++++ VEGFR2/KDR, IC50: 4 nM	+ VEGFR3/FLT4, IC50: 190 nM	FLT3	99%+
Vatalanib 2HCl	+ VEGFR1/FLT1, IC50: 77 nM	++ VEGFR2/Flk1, IC50: 270 nM VEGFR2/KDR, IC50: 37 nM	+ VEGFR3/FLT4, IC50: 660 nM	c-Kit,c-Fms/CSF1R	99%+
Axitinib	++++ VEGFR1/FLT1, IC50: 0.1 nM	++++ VEGFR2/Flk1, IC50: 0.18 nM VEGFR2/KDR, IC50: 0.2 nM			98%
Dovitinib	+++ VEGFR1/FLT1, IC50: 10 nM	+++ VEGFR2/Flk1, IC50: 13 nM	+++ VEGFR3/FLT4, IC50: 8 nM	FLT3,c-Kit	99%+
ZM 306416	+ VEGFR1, IC50: 0.33 μM			Src	99%+
KRN-633	+ VEGFR1, IC50: 170 nM	+ VEGFR2, IC50: 160 nM	+ VEGFR3, IC50: 125 nM	BTK,c-Kit	98%
OSI-930	+++ FLT1, IC50: 8 nM	+++ KDR, IC50: 9 nM			99%+
Lenvatinib	++ VEGFR1/FLT1, IC50: 22 nM	++++ VEGFR2/KDR, IC50: 4.0 nM	+++ VEGFR3/FLT4, IC50: 5.2 nM		98%
NVP-BAW2881	+ hVEGFR1, IC50: 820 nM	+++ mVEGF2, IC50: 165 nM hVEGFR2, IC50: 9 nM	+ hVEGFR3, IC50: 420 nM		99%
Cediranib	+++ VEGFR1/FLT1, IC50: 5 nM	++++ VEGFR2/KDR, IC50: 0.5 nM		c-Kit	99%+
Nintedanib	++ VEGFR1, IC50: 34 nM	+++ VEGFR2, IC50: 13 nM	+++ VEGFR3, IC50: 13 nM	FLT3	99+%
BMS-794833		++ VEGFR2, IC50: 15 nM			99%+
SKLB1002		++ VEGFR2, IC50: 32 nM			99%
Cabozantinib S-malate		++++ VEGFR2/KDR, IC50: 0.035 nM			99+%
Ki8751		++++ VEGFR2, IC50: 0.9 nM		c-Kit	99%
SU 5402		++ VEGFR2, IC50: 20 nM			98%
Apatinib mesylate		++++ VEGFR2, IC50: 1 nM		RET	98+%
Ponatinib		++++ VEGFR2, IC50: 1.5 nM			98%
LY2874455		+++ VEGFR2, IC50: 7 nM			99%+
ZM323881 HCl		++++ VEGFR2, IC50: <2 nM			98%
AZD2932		+++ VEGFR-2, IC50: 8 nM		c-Kit	99%
Cabozantinib		++++ VEGFR2/KDR, IC50: 0.035 nM			98%
Sorafenib		++ VEGFR2/Flk1, IC50: 90 nM VEGFR2, IC50: 90 nM			99%
CYC-116		++ VEGFR2, Ki: 44 nM		FLT3	99%+
Golvatinib		++ VEGFR2, IC50: 16 nM			99%+
Sunitinib		+ VEGFR2 , IC50: 80 nM		FLT3	98%
RAF265		++ VEGFR2, EC50: 30 nM			99%+
PD173074					99%+
BFH772		++++ VEGFR2, IC50: 3 nM			98%
Semaxinib		+ VEGFR2/Flk1, IC50: 1.23 μM			98%
Vandetanib		++ VEGFR2, IC50: 40 nM	+ VEGFR3, IC50: 110 nM	EGFR	99%
SAR131675			++ VEGFR3, IC50: 23 nM		99%+
ENMD-2076		+ VEGFR2/KDR, IC50: 58.2 nM	++ VEGFR3/FLT4, IC50: 15.9 nM	FLT3,RET	98%
Telatinib		+++ VEGFR2, IC50: 6 nM	++++ VEGFR3, IC50: 4 nM	c-Kit	99%+
1. 鼠标悬停在“+”上可以显示相关IC50的具体数值。"+"越多，抑制作用越强。2. "✔"表示该化合物对相应的亚型有抑制作用，但抑制强度暂时没有相关数据。

NVP-BAW2881 生物活性

靶点	VEGFR1 hVEGFR1, IC50:820 nM VEGFR3 hVEGFR3, IC50:420 nM VEGFR2 mVEGF2, IC50:165 nM hVEGFR2, IC50:9 nM
描述	BAW2881 is a vascular endothelial growth factor (VEGF) receptor tyrosine-kinase inhibitor that potently inhibits VEGFR1-3 at 1.0-4.3 nanomolar (nM) concentrations and inhibits PDGFRβ, c-Kit, and RET at 45-72 nM concentrations.

NVP-BAW2881 细胞实验

Cell Line Lymphatic Endothelial Cells (LECs) Human Umbilical Vein Endothelial Cells (HUVECs) Lymphatic endothelial cells (LECs) Human umbilical vein endothelial cells (HUVECs)	Concentration	Treated Time	Description	References
Lymphatic Endothelial Cells (LECs)	1 nM to 1 μM	72 h	NVP-BAW2881 significantly inhibited VEGF-A and VEGF-C-induced proliferation, migration, and tube formation in LECs.	Am J Pathol. 2008 Jul;173(1):265-77.
Human Umbilical Vein Endothelial Cells (HUVECs)	1 nM to 1 μM	72 h	NVP-BAW2881 significantly inhibited VEGF-A-induced proliferation, migration, and tube formation in HUVECs.	Am J Pathol. 2008 Jul;173(1):265-77.
Lymphatic endothelial cells (LECs)	1 nM - 1 μM	72 h	NVP-BAW2881 significantly inhibited VEGF-A and VEGF-C-induced proliferation of LECs.	Am J Pathol. 2008 Jul;173(1):265-77.
Human umbilical vein endothelial cells (HUVECs)	1 nM - 1 μM	72 h	NVP-BAW2881 significantly inhibited VEGF-A-induced proliferation of HUVECs.	Am J Pathol. 2008 Jul;173(1):265-77.

NVP-BAW2881 动物实验

Species Mice Mice and domestic pigs	Animal Model Transgenic mouse model of psoriasis K14/VEGF-A transgenic mouse model and UVB-induced skin inflammation model	Administration	Dosage	Frequency	Description	References
Mice	Transgenic mouse model of psoriasis	Oral	25 mg/kg	Once daily for 14 days	NVP-BAW2881 significantly reduced psoriasis-like skin inflammation, decreased the number of blood and lymphatic vessels, and normalized the epidermal architecture.	Am J Pathol. 2008 Jul;173(1):265-77.
Mice and domestic pigs	K14/VEGF-A transgenic mouse model and UVB-induced skin inflammation model	Oral and topical administration	Oral 25 mg/kg/day, topical 0.1% to 0.5%	Oral once daily, topical twice daily for 14 days	NVP-BAW2881 significantly reduced skin inflammation symptoms, including decreased numbers of blood and lymphatic vessels, reduced leukocyte infiltration, and normalized epidermal architecture.	Am J Pathol. 2008 Jul;173(1):265-77.

NVP-BAW2881 参考文献

[1]Bold G, Schnell C, et al. A Novel Potent Oral Series of VEGFR2 Inhibitors Abrogate Tumor Growth by Inhibiting Angiogenesis. J Med Chem. 2016 Jan 14;59(1):132-46.

[2]Halin C, Fahrngruber H, et al. Inhibition of chronic and acute skin inflammation by treatment with a vascular endothelial growth factor receptor tyrosine kinase inhibitor. Am J Pathol. 2008 Jul;173(1):265-77.

NVP-BAW2881 实验方案

计算器

存储液制备

1mg

5mg

10mg

1 mM

5 mM

10 mM

2.36mL

0.47mL

0.24mL

11.78mL

2.36mL

1.18mL

23.56mL

4.71mL

2.36mL

NVP-BAW2881 技术信息

CAS号	861875-60-7
分子式	C₂₂H₁₅F₃N₄O₂
分子量	424.38
SMILES Code	O=C(NC1=CC=CC(C(F)(F)F)=C1)C2=C3C=CC(OC4=NC(N)=NC=C4)=CC3=CC=C2
MDL No.	MFCD30343850

别名	BAW2881
运输	蓝冰
InChI Key	MLLQJNIKDWEEFT-UHFFFAOYSA-N
Pubchem ID	16004702

存储条件

In solvent -20°C: 3-6个月 -80°C: 12个月

Pure form Keep in dark place, inert atmosphere, 2-8°C

溶解方案

细胞实验：

DMSO: 35 mg/mL(82.47 mM)，注意：DMSO长时间开封后，会吸水并导致溶解能力下降，请避免使用长期开封的DMSO

动物实验：请根据您的动物给药指南选择适当的溶解方案。
以下溶解方案都请先按照体外实验的方式配制澄清的储备液，再依次添加助溶剂：
——为保证实验结果的可靠性，澄清的储备液可以根据储存条件，适当保存；体内实验的工作液，建议现用现配，当天使用；以下溶剂前显示的百分比是指该溶剂在终溶液中的体积占比；如在配制过程中出现沉淀、析出现象，可以通过加热和/或超声的方式助溶

方案一

方案二

NVP-BAW2881 {[allProObj[0].p_purity_real_show]}

NVP-BAW2881 纯度/质量文件产品仅供科研

全球学术期刊中引用的产品

NVP-BAW2881 质控信息

NVP-BAW2881 生物活性

NVP-BAW2881 细胞实验

NVP-BAW2881 动物实验

NVP-BAW2881 参考文献

NVP-BAW2881 实验方案

NVP-BAW2881 技术信息

最近浏览的产品

大规格询价

摩尔计算器

靶点

总药量计算器

工作液计算器

细胞研究

临床研究

确认信息

热门区域

A

B

C

F

G

H

J

L

N

Q

S

T

X

Y

Z

VEGFR1	hVEGFR1, IC50:820 nM
VEGFR3	hVEGFR3, IC50:420 nM
VEGFR2	mVEGF2, IC50:165 nM hVEGFR2, IC50:9 nM

NVP-BAW2881 {[allProObj[0].p_purity_real_show]}

NVP-BAW2881 纯度/质量文件 产品仅供科研

全球学术期刊中引用的产品

NVP-BAW2881 质控信息

NVP-BAW2881 生物活性

NVP-BAW2881 细胞实验

NVP-BAW2881 动物实验

NVP-BAW2881 参考文献

NVP-BAW2881 实验方案

NVP-BAW2881 技术信息

最近浏览的产品

大规格询价

摩尔计算器

靶点

总药量计算器

工作液计算器

细胞研究

临床研究

确认信息

请登录您的专属账户

热门区域

A

B

C

F

G

H

J

L

N

Q

S

T

X

Y

Z

NVP-BAW2881 纯度/质量文件产品仅供科研